Neurocrine Biosciences, Inc. (BVMF:N1BI34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 78.50B +27.8% |
| Revenue (ttm) | 16.18B +28.6% |
| Net Income | 3.49B +118.6% |
| EPS | 33.92 +119.9% |
| Shares Out | n/a |
| PE Ratio | 22.51 |
| Forward PE | 13.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 193 |
| Open | 39.84 |
| Previous Close | 39.84 |
| Day's Range | 39.84 - 39.84 |
| 52-Week Range | 31.51 - 44.18 |
| Beta | 0.34 |
| RSI | 71.50 |
| Earnings Date | May 5, 2026 |
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical develo... [Read more]
Financial Performance
In 2025, Neurocrine Biosciences's revenue was $2.86 billion, an increase of 21.45% compared to the previous year's $2.36 billion. Earnings were $478.60 million, an increase of 40.23%.
Financial numbers in USD Financial StatementsNews
Neurocrine announces new data from a clinician survey in Ingrezza
Neurocrine (NBIX) Biosciences announced the presentation of new data from a clinician survey highlighting the functional impact experienced by patients with mild tardive dyskinesia, or TD, severity an...
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
Clinician survey showed 90% of patients with mild tardive dyskinesia experienced emotional, social or physical impairment Following initiation of INGREZZA, 96% of patients with mild tardive dyskinesia...
Neurocrine completes acquisition of Soleno Therapeutics
Neurocrine Biosciences (NBIX) announced the completion of its acquisition of Soleno Therapeutics (SLNO), strengthening the company’s leadership in endocrinology and rare disease. As of May 18, Soleno’...
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
Strengthens Neurocrine's rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome Adds recently launched therapy with strong early adoption...
4basebio Announces Appointment of Chief Financial Officer and Board Changes
Richard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering for listed and private companies, including two major exits and over $400m raised Cambridge, UK, 14 M...
Neurocrine Biosciences Transcript: Bank of America Global Healthcare Conference 2026
Strong Q1 performance was driven by INGREZZA, CRENESSITY, and the addition of VYKAT XR, with all products showing durable growth and long patent protection. The pipeline is robust, with key phase III readouts expected in 2027–2028, and the Soleno acquisition is immediately accretive.
Neurocrine price target raised to $185 from $177 at JPMorgan
JPMorgan analyst Anupam Rama raised the firm’s price target on Neurocrine (NBIX) to $185 from $177 and keeps an Overweight rating on the shares.
Neurocrine price target raised to $155 from $140 at Truist
Truist analyst Danielle Brill raised the firm’s price target on Neurocrine (NBIX) to $155 from $140 and keeps a Buy rating on the shares. Both Ingrezza and Crenessity sales exceeded…
Neurocrine price target raised to $155 from $150 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Neurocrine (NBIX) to $155 from $150 and keeps a Hold rating on the shares.
Neurocrine treatment of Friedreich ataxia granted orphan designation
Neurocrine (NBIX) Biosciences was granted FDA orphan designation for a treatment of Friedreich ataxia, according to a post to the agency’s website.
Neurocrine price target raised to $246 from $242 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on Neurocrine (NBIX) to $246 from $242 and keeps a Buy rating on the shares. The company reported a Q1 beat…
Neurocrine price target raised to $207 from $190 at Piper Sandler
Piper Sandler raised the firm’s price target on Neurocrine (NBIX) to $207 from $190 and keeps an Overweight rating on the shares following quarterly results. Taking a step back, the…
Neurocrine price target raised to $191 from $185 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Neurocrine (NBIX) to $191 from $185 and keeps an Equal Weight rating on the shares. Neurocrine delivered a “strong” Q1 and Ingrezza…
Neurocrine price target raised to $230 from $220 at Oppenheimer
Oppenheimer raised the firm’s price target on Neurocrine (NBIX) to $230 from $220 and keeps an Outperform rating on the shares. The firm’s conviction in Neurocrine strengthened following impressive Q1...
Neurocrine price target raised to $155 from $140 at Truist
Truist analyst Danielle Brill raised the firm’s price target on Neurocrine (NBIX) to $155 from $140 and keeps a Buy rating on the shares. The firm updated its Neurocrine model…
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
New algorithms developed by expert clinical endocrinologists provide clear, practical recommendations for healthcare providers to reduce supraphysiologic glucocorticoid (GC) doses in patients with cla...
Neurocrine Biosciences Earnings Call Transcript: Q1 2026
Q1 2026 saw record net product sales over $800M, up 44% year-over-year, led by INGREZZA and CRENESSITY. Strong commercial execution, robust pipeline progress, and the pending Soleno acquisition position the company for continued growth in 2026.
Neurocrine Biosciences Earnings release: Q1 2026
Neurocrine Biosciences released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Neurocrine Biosciences Quarterly report: Q1 2026
Neurocrine Biosciences has published its Q1 2026 quarterly earnings report on May 5, 2026.
Neurocrine Biosciences Slides: Q1 2026
Neurocrine Biosciences has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Neurocrine reports Q1 adjusted EPS $1.94, consensus $1.70
Reports Q1 revenue $811M, consensus $767.88M. “Neurocrine’s (NBIX) strong first-quarter performance reflects continued momentum across our commercial portfolio, as we advance our growth strategy and d...
Neurocrine backs FY26 Ingrezza net product sales $2.7B-$2.8B
16:02 EDT Neurocrine (NBIX) backs FY26 Ingrezza net product sales $2.7B-$2.8B
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKAT TM XR (diazoxide choline)...
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026
SAN DIEGO, May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the Bank of America Health Care Conference 2026 at 11:20 a.m....
Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment
Approximately 1 in 5 surveyed working adults with tardive dyskinesia reported quitting their job due to untreated involuntary movements1 Respondents also reported missing an average of 8 hours of work...